Loading clinical trials...

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394•pharmaand GmbH

Summary

The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)
•Received 1 or 2 prior treatment regimens for advanced or metastatic disease
•Confirmed radiologic disease progression during or following recent treatment
•Mandatory biopsy is required during screening
•Measurable disease per RECIST v1.1
•Adequate organ function
•ECOG 0 or 1

Exclusion Criteria

•Prior treatment with a PARP inhibitor
•Symptomatic and/or untreated CNS metastases
•Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib

Locations (64)

Pinnacle Oncology, Honor Health

Scottsdale, Arizona, United States

University of California San Diego (UCSD), Moores Cancer Center

La Jolla, California, United States

University of California, Los Angeles (UCLA)

Los Angeles, California, United States

Universityof California, Irvine

Orange, California, United States

Saint John's Health Center - John Wayne Cancer Institute (JWCI)

Santa Monica, California, United States

Stanford University School of Medicine

Stanford, California, United States

Hartford Health Care Cancer Institute

Hartford, Connecticut, United States

Eastern Connecticut Hematology & Oncology Associates (ECHO)

Norwich, Connecticut, United States

Medstar Georgetown University Medical Center

Washington D.C., District of Columbia, United States

Miami Cancer Institute, Baptist Health South Florida

Miami, Florida, United States

Key Dates

Start Date

June 1, 2018

Primary Completion Date

December 12, 2019

Completion Date

January 15, 2020

Last Updated

June 9, 2023

Enrollment

ACTUAL participants

Conditions

Bladder CancerUrothelial CarcinomaMetastatic Urothelial CarcinomaRenal Pelvis CarcinomaUreter CarcinomaUrinary Bladder CarcinomaUrethra CarcinomaMuscle Invasive Bladder Cancer

Interventions

Rucaparib

DRUG

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITINGPHASE2/PHASE3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241

Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial Carcinoma+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 9, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)